Drug Trial Radar · NCT00712348
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
Last checked: Nov 20, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Dec 2008
Primary completion
Apr 2013
Study completion May 2013
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 10, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
Conditions
- Gaucher Disease
Interventions
Taliglucerase alfaDrug
Intravenous infusion every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- HemoglobinTime frame: Every 3 months from Baseline to Month 9
Locations
10 sites in 6 countries. Site status is shown where the registry gives one.
University Research Foundation for Lysosomal Storage Diseases, Inc.
Coral Springs, Florida
Department of Human Genetics, Emory University School of Medicine
Decatur, Georgia
Neurogenetics, NYU at Rivergate
New York, New York
Bone Marrow Transplant Service, The Royal Melbourne Hospital
Parkville, Victoria, Australia
Mount Sinai Hospital
Toronto, Ontario, Canada
Rambam Medical Center
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Sala de Hematologia, Hospital Universitario Miguel Servet
Zaragoza, Spain
Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust
Cambridge, United Kingdom
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.